Top 5 Biopharma Stocks for the New Health Era

Currently, our screening includes 23 biopharma stocks that have risen by at least 10% in the last 20 days. However, not every price increase is synonymous with long-term return potential. In many cases, the short-term growth is purely speculative, as the companies in question have not yet generated any revenue, and it is unclear when this will change. In other situations, these are stocks that have experienced a significant price decline and are now merely showing a small sign of life. Instead, I have focused today on five stocks that can justify...